Orion Oyj ORNAV.HE
Nasdaq Helsinki · Healthcare · Drug Manufacturers - General
101.00 EUR
+0.0%
2026-11-06
Keep this stock on your watchlist and set email alerts for prices, reports and important announcements where available.
Annual accounts for Orion
| EUR million | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 1,341 | 1,190 | 1,542 | 1,890 |
| EBITDA | 489 | 329 | 514 | 693 |
| Net income | 350 | 217 | 330 | 500 |
| Balance sheet | ||||
| Equity | 908 | 890 | 1,005 | 1,284 |
| Total debt | 214 | 200 | 327 | 305 |
| Cash | 333 | 107 | 206 | 161 |
| Net debt | −119 | 93 | 122 | 144 |
| Ratios and per share | ||||
| EBITDA margin | 36.5% | 27.6% | 33.3% | 36.7% |
| Profit margin | 26.1% | 18.2% | 21.4% | 26.5% |
| Return on equity | 38.5% | 24.4% | 32.8% | 38.9% |
| Earnings/share (EUR) | 2.49 | 1.54 | 2.35 | 3.56 |
| Book value/share (EUR) | 6.48 | 6.34 | 7.15 | 9.13 |
| Shares outstanding (M) | 140 | 140 | 141 | 141 |
From the annual statements (Yahoo Finance), in the currency the company reports in. Per-share figures use the shares at the year end. Charts and annual figures →
Key figures
| P/E | 28.4 |
| P/B | 11.1 |
| EV / EBITDA | 20.7 |
| Net debt / EBITDA | 0.2 |
| Return on equity | 39.0% |
| Profit margin | 26.5% |
| Beta 1Y | 0.37 |
| Revenue growth 1Y | +22.5% |
| Revenue CAGR 3Y | +12.1% |
| Earnings/share CAGR 3Y | +12.6% |
| ROE avg. 3Y | 32.0% |
Ratios use the latest annual report that was public 90 days after the year end.
Dividends per share (EUR)
| 2026 | 1.80 |
| 2025 | 1.64 |
| 2024 | 1.62 |
| 2023 | 1.60 |
| 2022 | 1.50 |
Not investment advice. Figures may contain errors from the data source.